SummitTX Capital’s Royalty Pharma RPRX Stock Holding History

SummitTX Capital’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-22,407	Closed	-$698K	–	978
2025 Q1	$698K	Buy	+22,407	New	+$710K	0.03%	474

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CIA

Caledonia Investments (Australia) Sydney NSW, Australia $2.93B AUM 37.21% 1-Year Est. Return

SummitTX Capital's RPRX Position: Q2 2025 in Review

SummitTX Capital sold out of Royalty Pharma (RPRX) in Q2 2025, closing a stake of 22,407 shares — an estimated $698K sold.

SummitTX Capital first reported a position in RPRX in Q1 2025 and held it in 1 quarter. The position peaked at $698K in Q1 2025. 454 funds tracked by Wall St. Rank hold RPRX as of Q2 2025.

SummitTX Capital reported no remaining Royalty Pharma position as of Q2 2025 after selling out during the quarter.
SummitTX Capital sold 22,407 Royalty Pharma shares in Q2 2025, an estimated $698K.
SummitTX Capital first reported a position in Royalty Pharma in Q1 2025 and held it in 1 quarter.
SummitTX Capital's Royalty Pharma position peaked at $698K in Q1 2025.
454 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2025.

Based on SummitTX Capital's 13F filing for Q2 2025, filed 14 Aug 2025.